Centene names Paul Diaz to board as Kenneth Burdick retires

Centene Corporation (NYSE: CNC) announced that Kenneth A. Burdick has retired from its board of directors and that Paul J. Diaz has been appointed to the board, both effective July 28, 2026.

Burdick joined Centene's board in January 2022. He previously served as executive vice president of products and markets at Centene and, before that, as chief executive officer of WellCare Health Plans.

Diaz is a managing partner at Cressey & Company, a private investment firm focused on healthcare. He previously served as president and chief executive officer of Myriad Genetics, Inc. and, before that, as president and chief executive officer of Kindred Healthcare. He has also served on the boards of DaVita and PharMerica.

Frederick H. Eppinger, chair of Centene's board, attributed the board change in a statement included in the press release: "We are pleased to welcome Paul Diaz to the Board. His extensive healthcare leadership experience, public company governance expertise and record of guiding organizations through growth and transformation will bring valuable perspective as Centene continues to advance its strategy and serve its members."

You May Also Be Interested In

• Bernstein SocGen Group Reiterates Outperform Rating on Centene (CNC), discusses CFO change
• L. Paris Watts-Stanfield resigns from IDEX Corp. board
• TON Strategy appoints Oscar Suarez to board as audit chair